J&J’s Darzalex nets first self-administered cancer injectable approval

What: Johnson & Johnson's Darzalex has received FDA approval for a self-administered injectable treatment for certain types of cancer.
Why: This approval marks a significant shift towards patient-centric care, allowing patients to administer the treatment themselves, potentially improving their quality of life.
Signal: The approval of Darzalex as a self-administered injectable treatment may signal a growing trend towards more convenient and accessible cancer treatments.
Target: Darzalex is expected to target a specific subset of patients with multiple myeloma, offering them a new treatment option.
Risk: As with any injectable treatment, there may be risks associated with self-administration, such as injection site reactions and allergic reactions.